<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189123</url>
  </required_header>
  <id_info>
    <org_study_id>080925</org_study_id>
    <secondary_id>5U18IP000184-03</secondary_id>
    <nct_id>NCT01189123</nct_id>
  </id_info>
  <brief_title>Cell Mediated Immunity in Older Adults</brief_title>
  <acronym>CMI</acronym>
  <official_title>Evaluation of Cell-mediated Immunity and Antibody Response to Influenza Vaccination and Correlates of Protection in Seniors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to study the immune response to the flu vaccine in people 65 years old and
      older. Only adults 65 years old and older and who are getting their flu vaccine are being
      asked to join in this study. The investigators plan to enroll approximately 100 people in
      this study in the 2010-2011 flu season. Vanderbilt is working with the Centers for Disease
      Control and Prevention on this study.

      There will be 5 study visits. Up to 4 tablespoons of blood from a vein will be obtained prior
      to the flu shot. Return visits will be 1, 2, and 4 weeks later,with up to 4 tablespoons of
      blood drawn again. Patients will be randomized to receive either the standard dose or the
      high dose flu vaccine. Both flu vaccines are FDA-approved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the 2010-2011 influenza season, approximately 100 adults â‰¥65 years of age will be
      enrolled. After consent, blood and serum will be collected and then subjects will be
      randomized to either standard or high dose influenza vaccine (both FDA approved vaccines).
      Vaccination will be done by an unblinded nurse. All further evaluations and analysis will be
      done by a blinded staff member. Medical history, relevant medications, and
      functional/nutritional status will be assessed at the first visit. Subjects will return
      (Table 3) for blood and serum draws on days 7, 14, 28 and for a serum blood draw after
      influenza season. No micronutrient samples will be drawn, but serum will be kept for possible
      vitamin D testing. During influenza season, subjects will answer a questionnaire about
      influenza-like illness (ILI) every two weeks (either by email or telephone) and will be asked
      to return for a nasal swab if an ILI is present. Comparisons will be made of the
      cell-mediated response of those vaccinated with standard versus high dose vaccines. Analyses
      will be done accounting for age, use of immunomodulating agents, and underlying medical
      conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cellular Immune Response</measure>
    <time_frame>3 years</time_frame>
    <description>comparison of CMI in high vs standard dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody Responses</measure>
    <time_frame>2 years</time_frame>
    <description>Hemagglutination inhibition antibody titers measured for standard vs high dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Immunity to Influenza Vaccine</condition>
  <arm_group>
    <arm_group_label>Standard dose influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluzone (Sanofi Pasteur)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Dose Fluzone by sanofi pasteur</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose influenza vaccine Sanofi-Pasteur</intervention_name>
    <description>High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection</description>
    <arm_group_label>High Dose Vaccine</arm_group_label>
    <other_name>High dose fluzone (Sanofi-Pasteur)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>fluzone by sanofi pasteur</intervention_name>
    <description>standard dose fluzone</description>
    <arm_group_label>Standard dose influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  aged 65+ years

        Exclusion Criteria:

          -  &lt;65 years

          -  influenza vaccine allergy

          -  Guillain-Barre

          -  weight &lt;110 pounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Keipp Talbot, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <results_first_submitted>January 17, 2014</results_first_submitted>
  <results_first_submitted_qc>January 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2014</results_first_posted>
  <last_update_submitted>April 3, 2014</last_update_submitted>
  <last_update_submitted_qc>April 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Keipp Talbot</investigator_full_name>
    <investigator_title>Assistant Professor, Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>vaccine</keyword>
  <keyword>cell mediated immunity</keyword>
  <keyword>elderly</keyword>
  <keyword>high dose influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Dose Influenza Vaccine</title>
          <description>Fluzone (Sanofi Pasteur)
fluzone by sanofi pasteur: standard dose fluzone
1 dose of vaccine was given IM</description>
        </group>
        <group group_id="P2">
          <title>High Dose Vaccine</title>
          <description>High Dose Fluzone by sanofi pasteur
High dose influenza vaccine Sanofi-Pasteur: High dose influenza vaccine Sanofi-Pasteur at standard dosing (1 IM injection)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Dose Influenza Vaccine</title>
          <description>Fluzone (Sanofi Pasteur)
fluzone by sanofi pasteur: standard dose fluzone</description>
        </group>
        <group group_id="B2">
          <title>High Dose Vaccine</title>
          <description>High Dose Fluzone by sanofi pasteur
High dose influenza vaccine Sanofi-Pasteur: High dose influenza vaccine Sanofi-Pasteur at standard dosing (1 IM injection)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74" lower_limit="68" upper_limit="77"/>
                    <measurement group_id="B2" value="72" lower_limit="67" upper_limit="79"/>
                    <measurement group_id="B3" value="73" lower_limit="67" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cellular Immune Response</title>
        <description>comparison of CMI in high vs standard dose</description>
        <time_frame>3 years</time_frame>
        <population>A subset of samples were chosen for testing since not enough money was available to test samples from all subjects. The samples were divided by randomization group (blinded to study staff -- they were called group A or group B). From each group, samples were randomly pulled.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine</title>
            <description>Fluzone (Sanofi Pasteur)
fluzone by sanofi pasteur: standard dose fluzone</description>
          </group>
          <group group_id="O2">
            <title>High Dose Vaccine</title>
            <description>High Dose Fluzone by sanofi pasteur
High dose influenza vaccine Sanofi-Pasteur: High dose influenza vaccine Sanofi-Pasteur at standard dosing (1 IM injection)</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular Immune Response</title>
          <description>comparison of CMI in high vs standard dose</description>
          <population>A subset of samples were chosen for testing since not enough money was available to test samples from all subjects. The samples were divided by randomization group (blinded to study staff -- they were called group A or group B). From each group, samples were randomly pulled.</population>
          <units>percentage of Stimulated cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+ IFNgamma at Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.239" lower_limit="0.124" upper_limit="0.396"/>
                    <measurement group_id="O2" value="0.137" lower_limit="0.098" upper_limit="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ TNF alpha Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.243" lower_limit="0.138" upper_limit="0.413"/>
                    <measurement group_id="O2" value="0.160" lower_limit="0.107" upper_limit="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ IL2 Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.174" lower_limit="0.107" upper_limit="0.260"/>
                    <measurement group_id="O2" value="0.147" lower_limit="0.124" upper_limit="0.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ IFNgamma at Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.162" lower_limit="0.101" upper_limit="0.311"/>
                    <measurement group_id="O2" value="0.191" lower_limit="0.130" upper_limit="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ TNF alpha Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.344" lower_limit="0.163" upper_limit="0.472"/>
                    <measurement group_id="O2" value="0.277" lower_limit="0.126" upper_limit="0.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ IL2 Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.200" lower_limit="0.107" upper_limit="0.276"/>
                    <measurement group_id="O2" value="0.167" lower_limit="0.108" upper_limit="0.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Responses</title>
        <description>Hemagglutination inhibition antibody titers measured for standard vs high dose</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine</title>
            <description>Fluzone (Sanofi Pasteur)
fluzone by sanofi pasteur: standard dose fluzone</description>
          </group>
          <group group_id="O2">
            <title>High Dose Vaccine</title>
            <description>High Dose Fluzone by sanofi pasteur
High dose influenza vaccine Sanofi-Pasteur: High dose influenza vaccine Sanofi-Pasteur at standard dosing (1 IM injection)</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Responses</title>
          <description>Hemagglutination inhibition antibody titers measured for standard vs high dose</description>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="10" upper_limit="80"/>
                    <measurement group_id="O2" value="80" lower_limit="40" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="O2" value="80" lower_limit="40" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="20" upper_limit="80"/>
                    <measurement group_id="O2" value="40" lower_limit="40" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Dose Influenza Vaccine</title>
          <description>Fluzone (Sanofi Pasteur)
fluzone by sanofi pasteur: standard dose fluzone</description>
        </group>
        <group group_id="E2">
          <title>High Dose Vaccine</title>
          <description>High Dose Fluzone by sanofi pasteur
High dose influenza vaccine Sanofi-Pasteur: High dose influenza vaccine Sanofi-Pasteur at standard dosing (1 IM injection)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to cost and time limitations, a random sample from each treatment group were pulled for CMI testing. Hence not all samples were tested.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Keipp Talbot</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6153222035</phone>
      <email>keipp.talbot@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

